Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.76
Bid: 5.02
Ask: 6.50
Change: -0.15 (-2.54%)
Spread: 1.48 (29.482%)
Open: 5.91
High: 0.00
Low: 0.00
Prev. Close: 5.91
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Arena soars on takeover; Accrol supply chain hit

Wed, 20th Oct 2021 10:56

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Arena Events Group PLC, up 43% at 20.30 pence, 12-month range 4.01p-21p. The firm - which services major events, supplying things such as temporary physical structures and seating - agrees to be taken over by Theta Bidco Ltd in deal worth enterprise value of GBP95.1 million. The suitor - owned by joint offerors IHC Industrial Holding LLC and Tasheel Holding Group LLC - will pay 21p per Arena share, being a 48% premium to Tuesday's closing price. It values Arena's entire issued share capital at GBP71.0 million. "IHC and Tasheel are both diversified holding companies, formed as part of initiatives to diversify and grow non-oil business sectors in the United Arab Emirates and Saudi Arabia respectively. Arena fits well into that diversification strategy, particularly given the growth potential of the temporary events structures market in the Middle East," they note.

----------

Reabold Resources PLC, up 19% at 0.1845p, 12-month range 0.15p-0.87p. Notes that Corallian Energy Ltd, in which it holds just under a 50% stake, has decided to undertake review of strategic options to maximise shareholder value. This will include fielding potential takeover offers for up to 100% of the firm. "Reabold remains supportive of Corallian, its board, and the timing of this strategic review. Reabold believes Corallian's flagship Victory gas development presents a compelling investment opportunity to any prospective investor," Reabold says.

----------

Real Good Food PLC, up 15% at 2.47p, 12-month range 1.42p-4.94p. The food manufacturer says revenue in six months to September 30 up 31% on a year ago and 0.7% above two years ago. Registers underlying earnings before interest, tax, depreciation and amortisation of GBP500,000 in period versus loss of GBP1.4 million a year ago. "We have made a good start to the year and the Group is well positioned for the seasonally busier second half of the year," says Executive Chair Mike Holt.

----------

Synairgen PLC, up 13% at 165.55p, 12-month range 74.8p-199.96p. The drug discovery and biotechnology company is informed that the external data safety monitoring board of the ACTIV-2 study has recommended that SNG001 advance into phase 3 in mild to moderate Covid-19 patients. "The advancement of SNG001 from phase 2 to phase 3 of the large ACTIV-2 trial is very welcome news and continues to build the case that our formulation of inhaled IFN-beta may have an important role in combatting CovidD-19 and future emerging virus threats," says Chief Executive Richard Marsden.

----------

AIM - LOSERS

----------

Accrol Group Holdings PLC, down 17% at 37.3p, 12-month range 33.50p-75.1p. The tissue converter notes "considerable" pressure on supply chains and higher costs, as well as shortage of HGV drivers restricting revenue growth. Says cost increases being successfully passed on, but there will be a time lag in passing on the full impact, resulting in earnings for financial year ending April 30 being "lower than previously expected".

----------

UK Oil & Gas PLC, down 7.5% at 0.1295p, 12-month range 0.1p-0.48p. Is "disappointed" by Isle of Wight Council's Planning Committee decision to refuse consent for the appraisal and testing of the Arreton oil and gas discovery. "Today's decision goes against last week's recommendation by the council's planning officers to approve the project. The company will now consider its position and whether to lodge an appeal with the Planning Inspectorate," it says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
5 Aug 2015 07:42

Synairgen Signs Research Collaboration Deal With Australia's Pharmaxis

Read more
22 Jul 2015 10:44

AstraZeneca starts next phase of testing on Synairgen asthma drug

(ShareCast News) - Synairgen announced AstraZeneca started another phase of testing on its asthma drug. AIM listed Synairgen said AstraZeneca begun its Phase IIa trial of the drug AZD9412 and expected results in early 2017. AstraZeneca would test 220 asthma patients whose conditions were exacerbate

Read more
22 Jul 2015 07:00

Synairgen Says AstraZeneca Begins Phase IIa Trial In Severe Asthma

Read more
22 Jun 2015 07:28

LONDON BRIEFING: Stocks Surge On Optimism For Greek Debt Deal

Read more
22 Jun 2015 05:13

AGM, EGM Calendar - Week Ahead

Read more
19 Jun 2015 15:14

AGM, EGM Calendar - Week Ahead

Read more
19 Jun 2015 05:21

AGM, EGM Calendar - Week Ahead

Read more
18 Jun 2015 15:06

AGM, EGM Calendar - Week Ahead

Read more
18 Jun 2015 05:27

AGM, EGM Calendar - Week Ahead

Read more
17 Jun 2015 14:56

AGM, EGM Calendar - Week Ahead

Read more
17 Jun 2015 05:23

AGM, EGM Calendar - Week Ahead

Read more
16 Jun 2015 15:03

AGM, EGM Calendar - Week Ahead

Read more
16 Jun 2015 05:23

AGM, EGM Calendar - Week Ahead

Read more
15 Jun 2015 14:52

AGM, EGM Calendar - Week Ahead

Read more
3 Mar 2015 08:38

Synairgen Swings To 2014 Pretax Profit On AstraZeneca Licence Deal

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.